Literature DB >> 12057558

Reliability of diagnosis of melanoma in situ.

Mosaad Megahed1, Margarete Schön, Dennis Selimovic, Michael P Schön.   

Abstract

Early and correct diagnosis of malignant melanoma is of utmost importance to ensure adequate treatment and the best outcome. Prompted by the death of a patient with an apparent metastasising melanoma in situ, we reassessed 104 people with this malignant disorder, whose diagnosis had been histopathologically verified. We did immunohistochemical analysis of cells with the melanocytic marker melan-A/MART-1, and results of this analysis showed that 30 (29%) of 104 patients had invasive melanomas. One patient died of distant metastases, and the tumour recurred in another. Our finding could be relevant for diagnosis and treatment of melanoma in situ.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12057558     DOI: 10.1016/S0140-6736(02)08741-X

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  13 in total

1.  Cutaneous melanoma in situ: translational evidence from a large population-based study.

Authors:  Simone Mocellin; Donato Nitti
Journal:  Oncologist       Date:  2011-05-31

2.  [Histology of malignant tumors caused by UV light].

Authors:  M Megahed
Journal:  Hautarzt       Date:  2012-10       Impact factor: 0.751

Review 3.  Conceptual approach to early melanoma detection: models, tools, issues and challenges.

Authors:  Shadi Damanpour; James M Grichnik
Journal:  Melanoma Manag       Date:  2015-11-24

4.  Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistance.

Authors:  Ali R Jazirehi; Dylan Arle
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

5.  Melanoma in situ: a case report from the patient's perspective.

Authors:  Craig A Bauman; Peter Emary; Tyler Damen; Heather Dixon
Journal:  J Can Chiropr Assoc       Date:  2018-04

Review 6.  Nanotechnology-Based Drug Delivery Systems for Melanoma Antitumoral Therapy: A Review.

Authors:  Roberta Balansin Rigon; Márcia Helena Oyafuso; Andressa Terumi Fujimura; Maíra Lima Gonçalez; Alice Haddad do Prado; Maria Palmira Daflon Gremião; Marlus Chorilli
Journal:  Biomed Res Int       Date:  2015-05-11       Impact factor: 3.411

7.  Clinical performance of the Nevisense system in cutaneous melanoma detection: an international, multicentre, prospective and blinded clinical trial on efficacy and safety.

Authors:  J Malvehy; A Hauschild; C Curiel-Lewandrowski; P Mohr; R Hofmann-Wellenhof; R Motley; C Berking; D Grossman; J Paoli; C Loquai; J Olah; U Reinhold; H Wenger; T Dirschka; S Davis; C Henderson; H Rabinovitz; J Welzel; D Schadendorf; U Birgersson
Journal:  Br J Dermatol       Date:  2014-10-19       Impact factor: 9.302

8.  An assessment of histological margins and recurrence of melanoma in situ.

Authors:  Kenneth M Joyce; Cormac W Joyce; Deirdre M Jones; Paul Donnellan; Alan J Hussey; Padraic J Regan; Jack L Kelly
Journal:  Plast Reconstr Surg Glob Open       Date:  2015-03-06

9.  Study of 448 cases of melanoma in situ in two hospitals in Rio de Janeiro.

Authors:  Luciana Pantaleão; Mayra Carrijo Rochael
Journal:  An Bras Dermatol       Date:  2017 Mar-Apr       Impact factor: 1.896

10.  Demethylzeylasteral inhibits cell proliferation and induces apoptosis through suppressing MCL1 in melanoma cells.

Authors:  Yuzu Zhao; Jiang He; Jun Li; Xingzhi Peng; Xianxing Wang; Zhen Dong; Erhu Zhao; Yaling Liu; Zonghui Wu; Hongjuan Cui
Journal:  Cell Death Dis       Date:  2017-10-26       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.